Concourse Financial Group Securities, Inc. Bio Atla, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 100.0%

20 transactions

Quarter	Operation	Price Per share
Q2 2025 Aug 12, 2025	BUY	$0.27 - $0.56 $0 - $0
Q1 2025 May 14, 2025	BUY	$0.28 - $0.68 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$0.59 - $2.37 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$1.17 - $2.05 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.37 - $3.92 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.88 - $3.46 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.27 - $3.18 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.7 - $3.07 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.7 - $3.07 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$2.83 - $3.87 $0 - $0
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$6.29 - $11.01 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$2.94 - $11.87 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$2.13 - $5.38 $0 - $0
Q1 2022 May 09, 2022	BUY	$4.38 - $18.78 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$19.0 - $30.95 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$29.44 - $43.74 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$38.07 - $56.17 $0 - $0
Q1 2021 May 13, 2021	BUY	$32.41 - $70.91 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$31.02 - $35.16 $0 - $0

Others Institutions Holding BCAB

# of Institutions

Shares Held

13.7M

Call Options Held

20.7K

Put Options Held

Acorn Capital Advisors, LLC New York, NY

4.84M
Shares

$3.38 Million
1.25% of portfolio
Vanguard Group Inc Valley Forge, PA

1.95M
Shares

$1.36 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

1.49M
Shares

$1.04 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

1.37M
Shares

$961,853
0.03% of portfolio
Black Rock Inc. New York, NY

792K
Shares

$554,092
0.0% of portfolio

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $25.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account